Abstract
Rationale
Though 5-HT plays an important role in the modulation of motor function, which is perturbed in depressive states, little is known concerning the influence of serotonin reuptake inhibitors (SSRIs) on locomotor activity (LA). Recently, we demonstrated that SSRIs, such as citalopram, enhance LA in mice exposed to a novel environment.
Objectives
This study examined the role of multiple classes of 5-HT receptor in citalopram-induced LA.
Methods
The most selective antagonists currently available were used.
Results
Citalopram-induced LA was dose-dependently attenuated by the 5-HT1B/1D receptor antagonists, S18127, GR125,743 and GR127,935, and by the selective 5-HT1B antagonist, SB224,289, but unaffected by the selective 5-HT1A antagonist, WAY100,635. The selective antagonists at 5-HT2A receptors, MDL100,907 and SR46,349 also dose-dependently attenuated induction of locomotion by citalopram, whereas the 5-HT2B antagonist, SB204,741, and the 5-HT2B/2C antagonist, SB206,553 were ineffective. Further, the selective 5-HT2C antagonist, SB242,084, potentiated the response to citalopram. Selective antagonists at 5-HT3 (ondansetron), 5-HT4 (GR125,487), 5-HT6 (SB271,046) and 5-HT7 (SB269,970) receptors did not significantly modify the action of citalopram. Underpinning these findings, SB224,289, GR125,743, MDL100,907 and SR46,349 likewise attenuated induction of locomotion by a further SSRI, fluvoxamine.
Conclusions
The locomotor response to SSRIs of mice exposed to a novel environment is mediated via 5-HT1B and 5-HT2A receptors. In view of the importance of motor function to the etiology and treatment of depression, the significance of these observations to the clinical actions of SSRIs will be of interest to elucidate.
Similar content being viewed by others
References
Audinot V, Newman-Tancredi A, Millan MJ (2001) Constitutive activity at serotonin 5-HT1D receptors: detection and quantification by homologous GTPγS versus [35S]-GTPγS binding isotherms. Neuropharmacology 40:57–64
Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S (2001) Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB242,084 but not the 5-HT1A receptor antagonist WAY100,635. Int J Neuropsychopharmacol 4:399–408
Bankson MG, Cunningham KA (2002a) 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 297:846–852
Bankson MG, Cunningham KA (2002b) Pharmacological studies of the acute effects to (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT1B/1D and 5-HT2 receptors. Neuropsychopharmacology 26:40–52
Barker EL, Blakely RD (1995) Norepinephrine and serotonin transporters: molecular targets for antidepressant drugs. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation in progress. Raven Press, New York, pp 321–334
Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152
Belzung C, Scearce-Levie K, Barreau S, Hen R (2000) Absence of cocaine-induced place conditioning in serotonin 5-HT1B receptor knock-out mice. Pharmacol Biochem Behav 66:221–225
Bourson A, Boess FG, Bös M (1998) Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol 125:1562–1566
Bowers BJ, Henry MB, Thielen RJ, McBride WJ (2000) Serotonin 5-HT2 receptor stimulation of dopamine release in the posterior but not anterior nucleus accumbens of the rat. J Neurochem 75:1625–1633
Bristow LJ, O'Connor D, Watts R, Duxon MS, Hutson PH (2000) Evidence for accelerated desensitisation of 5-HT2C receptors following combined treatment with fluoxetine and the 5-HT1A receptor antagonist, WAY100,635, in the rat. Neuropharmacology 39:1222–1236
Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ (2002) Induction of locomotion in mice exposed to a novel environment by inhibition of serotonin reuptake a pharmacological characterization of diverse classes of antidepressant agent. Pharmacol Biochem Behav 71:667–680
Bronsert MR, Mead AN, Hen R, Rocha BA (2001) Amphetamine-induced locomotor activation in 5-HT1B knockout mice: effects of injection route on acute and sensitized responses. Behav Pharmacol 12:549–555
Bruinvels AT, Palacios JM, Hoyer D (1993) Autoradiographic characterization and localization of 5-HT1D compared with 5-HT1B binding sites in rat brain. Naunyn-Schmiedelberg's Arch Pharmacol 347:569–582
Caldecott-Hazard S, Morgan DG, DeLeon-Jones F, Overstreet DH, Janowsky D (1991) Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories. Synapse 9:251–301
Caligiuri MP, Ellwanger J (2000) Motor and cognitive aspects of motor retardation in depression. J Affect Disord 57:83–93
Callaway CW, Geyer MA (1992) Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist. J Pharmacol Exp Ther 263:318–326
Callaway CW, Rempel N, Peng RY, Geyer MA (1992) Serotonin 5-HT1-like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology 7:113–127
Chaouloff F, Courvoisier H, Moisan MP, Mormède P (1999) GR127935 reduces basal locomotor activity and prevents RU24969 but not d-amphetamine-induced hyperlocomotion, in the Wistar-Kyoto hyperactive (WKHA) rat. Psychopharmacology 141:326–331
Cheetham SC, Heal DJ (1993) Evidence that RU 24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT1B receptor. Br J Pharmacol 110:1621–1629
Clemett DA, Cockett MI, Marsden CA, Fone KCF (1998) Antisense oligonucleotide-induced reduction in 5-hydroxytryptamine7 receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function. J Neurochem 71:1271–1279
Clemett F, De Vos A, Bourin M (2001) Involvement of 5-HT2C receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. Eur Neuropsychopharmacol 11:145–152
Consolo S, Arnaboldi S, Ramponi S, Nannini L, Ladinsky H, Haldi G (1996) Endogenous serotonin facilitates in vivo acetylcholine release in rat frontal cortex through 5-HT1B receptors. J Pharmacol Exp Ther 277:823–830
Cussac D, Newman-Tancredi A, Quentric Y, Carpentier N, Poissonnet G, Parmentier JG, Goldstein S, Millan MJ (2002) An innovative strategy for characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: Influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn-Schmiedeberg's Arch Pharmacol 365: 242–252
Davidson C, Stanford JA (1995) Evidence that 5-hydroxytryptamine release in rat dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1d autoreceptors. Br J Pharmacol 114:1107–1109
Daws LC, Gould GG, Teicher SD, Gerhardt GA, Frazer A (2000) 5-HT1B receptor-mediated regulation of serotonin clearance in rat hippocampus in vivo. J Neurochem 75:213–2122
Dawson LC, Nguyen HQ, Li P (2001) The 5-HT6 receptor antagonist SB271,046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25:662–668
De Deurwaerdère P, Spampinato U (2001) The nigrostriatal dopamine system: a neglected target for 5-HT2C receptors. Trends Pharmacol Sci 22:502–503
De Deurwaerdère P, Uirondel M, Bonhomme N, Lucas G, Cheramy A, Spampinato U (1997) Serotonin stimulation of 5-HT4 receptors indirectly enhances in vivo dopamine release in the rat striatum. J Neurochem 68:195–203
De Deurwaerdère P, Stinus L, Spampinato U (1998) Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. J Neurosci 18:6528–6538
Dekeyne A, Girardon S, Millan MJ (1999) Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis. Neuropharmacology 38:415–423
Dekeyne A, Denorme B, Monneyron S, Millan MJ (2000) Citalopram reduces social interaction in rats by activation of serotonin (5-HT)2C receptors. Neuropharmacology 39:1114–1117
De La Garza R, Cunningham KA (2000) The effects of the 5-hydroxytryptamine1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin on spontaneous activity, cocaine-induced hyperactivity and behavioral sensitization: a microanalysis of locomotor activity. J Pharmacol Exp Ther 292:610–617
Di Matteo V, De Blasi A, Di Giulio C, Esposito E (2001) Role of 5-HT2C receptors in the control of central dopamine function. Trends Pharmacol Sci 22:229–232
Dirks A, Pattij T, Bouwknecht JA, Westphal TT, Hijzen TH, Groenink L, van der Gugten, Oosting RS, Hen R, Geyer MA, Olivier B (2001) 5-HT1B receptor knockout, but not 5-HT1A receptor knockout mice, show reduced startle reactivity and footshock-induced sensitization, as measured with the acoustic startle response. Behav Brain Res 118:169–178
Doherty MD, Pickel VM (2000) Ultrastructural localization of the serotonin2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res 864:176–185
Doménech T, Beleta J, Palacios JM (1997) Characterization of human serotonin1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5-HT1B/1D receptor antagonist. Naunyn-Schmiedeberg's Arch Pharmacol 356:328–334
Duxon MS, Kennett GA, Lightowler S (1997) Activation of 5-HT2B receptors in the medial amydgala causes anxiolysis in the social interaction test in the rat. Neuropharmacology 36:601–608
Evrard A, Laporte AM, Chastanet M, Hen R, Hamon M, Adrien J (1999) 5-HT1A and 5-HT1B receptors control the firing of serotoninergic neurons in the dorsal raphe nucleus of the mouse: studies in 5-HT1B knock-out mice. Eur J Neurosci 11:3823–3831
Fletcher PJ, Korth KM (1999) Activation of 5-HT1B receptors in the nucleus accumbens reduces amphetamine-induced enhancement of responding for conditioned reward. Psychopharmacology 142:165–174
Fletcher B, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLenachan A, Stanhope KJ, Critchley DJP, Childs KJ, Middlefell VC, Lanfumey L, Corradetti R, Laporte AM, Gozlan H, Hamon M, Dourish CT (1996) Electrophysiological biochemical, neurohormonal and behavioural studies with WAY100,635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73:337–353
Fletcher PJ, Korth KM, Robinson SR, Baker GB (2002) Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology 162:282–291
Fontana DJ, Daniels SE, Wong EHK (1997) The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation. Neuropharmacology 4/5:689–696
Gaster LM, Blaney FE, Davies S, Duckworth M, Ham P, Jenkins S, Jennings AJ, Joiner GF, King FD, Mulholland KR, Wyman PA, Hagan JJ, Hatcher J, Jones BJ, Middlemiss DN, Price GW, Riley G, Roberts C, Routledge C, Selkirk J, Slade PD (1998) The selective 5-HT1B receptor inverse agonist 1′-methyl-5-[[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]-2,3,6,7-tetrahydro-spiro[furo[2,3-f]indole-3,4′-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem 41:1218–1235
Gerald C, Martres MP, Lefèvre K (1997) Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res 746:207–219
Geyer MA (1996) Serotonergic functions in arousal and motor activity. Behav Brain Res 73:31–36
Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 84:413–429
Gobert A, Dekeyne A, Millan MJ (2000a) The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572. Neuropharmacology 39:1608–1616
Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ (2000b) Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205–221
Goodnick PJ, Goldstein BJ (1998) Selective serotonin reuptake inhibitors in affective disorders—I. Basic pharmacology. J Psychopharmacol 12:S5-S20
Griebel G, Perrault G, Sanger DJ (1997) A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 36:793–802
Hagen JD, Pierce PA, Peroutka SJ (1994) Differential binding of ergot compounds to human vs rat 5-HT2 cortical regions. Biol Signals 3:223–229
Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, Piper D, Smith MI, Upton N, Medhurst AD, Middlemiss DN, Riley GJ, Lovell PJ, Bromidge SM, Thomas DR (2000) Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist. Br J Pharmacol 130:539–548
Harrison AA, Parson LH, Koob GF, Markou A (1999) RU 24969, a 5-HT1A/1B agonist, elevates brain stimulation reward thresholds: an effect reversed by GR127935, a 5-HT1B/1D agonist. Psychopharmacology 141:242–250
Herges S, Taylor DA (1998) Involvement of serotonin in the modulation of cocaine-induced locomotor activity in the rat. Pharmacol Biochem Behav 59:595–611
Hillegaart V (1990) Effects of local application of 5-HT and 8-OH-DPAT into the dorsal and median raphe nuclei on motor activity in the rat. Physiol Behav 48:143–148
Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE (1993) Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 231:223–226
Johnson SW, Mercuri NB, North RA (1992) 5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons. J Neurosci 12:2000–2006
Jones BJ, Costall B, Domeney AM (1988) The potential anxiolytic activity of GR38032F, a 5-HT3 receptor antagonist. Br J Pharmacol 93:985–993
Kalkman HO, Soar J (1990) Determination of the 5-HT receptor subtype involved in 8-OH-DPAT induced hyperlocomotion potential difficulties arising from inadequate pharmacological tools. Eur J Pharmacol 191:383–390
Kankaanpää A, Meririnne E, Seppälä T (2002) 5-HT3 receptor antagonist MDL 72222 attenuates cocaine-and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat. Psychopharmacology 159:341–350
Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter GS, Forbes IT, Ham P, Blackburn TP (1996) In vitro and in vivo profiles of SB206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117:427–434
Kennett GA, Wood MD,Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP (1997) SB242,084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36:609–620
Knobelman DA, Hen R, Lucki I (2001) Genetic regulation of extracellular serotonin by 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptors in different brain regions of the mouse. J Pharmacol Exp Ther 298:1083–1091
Lucas G, Di Matteo V, De Deurwaerdère P, Porras G, Martin-Ruiz R, Artigas F, Esposito E, Spampinato U (2001) Neurochemical and electrophysiological evidence that 5-HT4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal, dopaminergic function. Eur J Neurosci 13:889–898
Lucki I, Ward HR, Frazer A (1989) Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 249:155–164
Maes M, Meltzer HY (1995) The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation in progress. Raven Press, New York, pp 933–944
Malleret G, Hen R, Guillou JL, Segu L, Buhot MC (1999) 5-HT1B receptor knock-out mice exhibit increased exploratory activity and enhanced spatial memory performance in the Morris water maze. J Neurosci 19:6757–6168
Martin JR, Bös M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichman J, Andrews JS, Berendsen HH, Broekkamp CL, Ruight CL, Kohler C, Delft AM (1998). 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913–924
Mayorga AJ, Dalvi A, Page ME, Zimov-Levinson S, Hen R, Lucki I (2001) Antidepressant-like behavioral effects in 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptor mutant mice. J Pharmacol Exp Ther 298:1101–1107
McCreary AC, Bankson MG, Cunningham KA (1999) Pharmacological studies of the acute and chronic effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine1A and 5-hydroxytryptamine1B/1D receptors. J Pharmacol Exp Ther 290:965–973
McMahon LR, Cunningham KA (1999) Antagonism of 5-hydroxytryptamine2A receptors attenuates hyperactivity induced by cocaine: putative role for 5-hydroxytryptamine4 receptors in the nucleus accumbens shell. J Pharmacol Exp Ther 291:300–307
McMahon LR, Cunningham KA (2001a) Antagonism of 5-hydroxytryptamine2A receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther 297:357–363
McMahon LR, Cunningham KA (2001b) Role of 5-HT2A and 5-HT2B/2C receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors. Neuropsychopharmacology 24:319–329
Menard J, Treit D (1999) Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci Biobehav Rev 23:591–613
Meneses A (1999) 5-HT system and cognition. Neurosci Biobehav Rev 23:1111–1125
Millan MJ (2000) Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 295:853–861
Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355–474
Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S (1997) 5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur J Pharmacol 325:9–12
Millan MJ, Brocco M, Gobert A, Bervoets K, Rivet JM, Newman-Tancredi A, Audinot V, Maurel S (1999a) Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419–4432
Millan MJ, Girardon S, Dekeyne A (1999b) 5-HT2C receptors are involved in the discriminative stimulus effects of citalopram in rats. Psychopharmacology 142:432–434
Millan MJ, Gobert A, Audinot V, Dekeyne A, Newman-Tancredi A (1999c) Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Neuropsychopharmacology 21:61S-67S
Millan MJ, Lejeune F, Gobert A (2000) Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14:114–138
Millan MJ, Dekeyne A, Papp M, Drieu La Rochelle C, MacSweeny C, Peglion JL, Brocco M (2001a) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioural profile in comparison to venlafaxine, reboxetine, citalopram and clomipramine. J Pharmacol Exp Ther 298:581–591
Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL (2001b) S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological and neurochemical profile in comparison to venlafaxine, reboxetine, citalopram and clomipramine. J Pharmacol Exp Ther 298:565–580
Millan MJ, Newman-Tancredi A, Lochon S, Touzard M, Aubry S, Audinot V (2002) Specific labelling of (serotonin 5-HT)1B receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743 a pharmacological characterization. Pharmacol Biochem Behav 71:589–598
Mittman SM, Geyer MA (1989) Effects of 5-HT1A agonists on locomotor and investigatory behaviors in rats differ from those of hallucinogens. Psychopharmacology 98:321–329
Moore NA, Tree B, Newton J, Visanji N (1999) 5-HT2A Receptors mediate pergolide-induced hyperactivity. Behav Pharmacol 10:S63
Moret C, Briley M (2000) The possible role of 5-HT1B/D receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 404:1–12
Morikawa H, Manzoni OJ, Crabbe JC, Williams JT (2000) Regulation of central synaptic transmission by 5-HT1B auto-and heteroceptors. Mol Pharmacol 58:1273–1278
Moser PC, Sanger DJ (1999) 5-HT1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats. Eur J Pharmacol 372:127–134
Munzar P, Justinova Z, Kutkat SW, Goldberg SR (2002) Differential involvement of 5-HT2A receptors in the discriminative-stimulus effects of cocaine and methamphetamine. Eur J Pharmacol 436:75–82
Neumaier JF, Sexton TJ, Yracheta J, Diaz AM, Brownfield M (2001) Localization of 5-HT7 receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression. J Chem Neuroanat 21:63–73
Newman-Tancredi A, Audinot V, Moreira C, Verrièle L, Millan MJ (2000) Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT1B receptor/G-protein stoichiometry. Mol Pharmacol 58:1042–1049
Ng NK, Lee HS, Wong PTH (1999) Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors. J Neurosci Res 55:600–607
Oberlander C, Demassey Y, Verdu A, Van de Velde D, Bardelay C (1987) Tolerance to the serotonin 5-HT1B agonist RU 24969 and effects on dopaminergic behavior. Eur J Pharmacol 139:205–214
Olivier B, Van Wijngaarden L, Soudijn W (2000) 5-HT3 receptor antagonists and anxiety; a preclinical and clinical review. Eur Neuropsychopharmacol 10:77–95
O'Neill MF, Conway MW (2001) Role of 5-HT1A and 5-HT1B receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology 24:391–398
O'Neill MF, Parameswaran T (1997) RU24969-induced behavioural syndrome requires activation of both 5-HT1A and 5-HT1B receptors. Psychopharmacology 132:255–260
O'Neill MF, Fernandez AG, Palacios JM (1996) GR 127935 blocks the locomotor and antidepressant-like effects of RU 24969 and the action of antidepressants in the mouse tail suspension test. Pharmacol Biochem Behav 53:535–539
O'Neill MF, Dobson DR, Sanger GJ (2000) 5-HT1B/1D receptor agonist, SKF99101H, induces locomotor hyperactivity in the guinea pig. Eur J Pharmacol 399:49–55
Otano A, Frechilla D, Cobreros A, Cruz-Orive LM, Insausti A, Insausti R, Hamon M, Del Rio J (1999) Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine6 receptors in rat nucleus accumbens by antisense oligonucleotides. Neuroscience 92:1001–1009
Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J (1996) Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. Psychopharmacology 126:234–240
Parsons LH, Koob GF, Weiss F (1999) RU24969, a 5-HT1B/1A receptor agonist, potentiates cocaine-induced increases in nucleus accumbens dopamine. Synapse 32:132–135
Paulus MA, Geyer MA (1992) The effects of MDMA and other methylenedioxy-substituted phenalkylamines on the structure of rat locomotor activity. Neuropsychopharmacology 7:15–31
Popik P (1999) Preclinical pharmacology of citalopram. J Clin Pharmacol 19:4S–22S
Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Gothert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN (1997) SB-216641 and BRL-15572-compounds to pharmacologically discriminative h5-HT1B and h5-HT1D receptors. Naunyn-Schmiedeberg's Arch Pharmacol 356:312–320
Prisco S, Esposito E (1995) Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol 116:1923–1931
Przegalinski E, Siwanowicz J, Nowak E, Papla I, Filip M (2001) Role of 5-HT1B receptors in the sensitization to amphetamine in mice. Eur J Pharmacol 422:91–99
Reavill C, Hatcher JP, Lewis VA, Sanger GJ, Hagan J (1998) 5-HT4 receptor antagonism does not affect motor and reward mechanisms in the rat. Eur J Pharmacol 357:115–120
Redrobe JP, MacSweeney CP, Bourin M (1996) The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol 318:213–220
Rempel NL, Callaway CW, Geyer MA (1993) Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology 8:201–211
Reneric JP, Lucki I (1998) Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology 136:190–197
Rinaldi-Carmona M, Congy C, Santucci V, Simiand J, Gautret B, Nelait G, Labeeuw B, Le Fur G, Soubrié P, Brelière JC (1992) Biochemical and pharmacological properties of SR46,349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J Pharmacol Exp Ther 262:759–768
Roberts C, Allen L, Langmead CJ, Hagan JJ, Middelmiss DN, Price GW (2001) The effect of SB-269970, a 5-HT receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. Br J Pharmacol 132:1574–1580
Routledge C, Bromidge SM, Moss SF, Price GW, Hirst W, Newman H, Riley G, Gager T, Stean T, Upton N, Clarke SE, Dodgson K, Brown AM, Middlemiss DN (2000) Characterization of SB-271046, a potent and selective 5-HT6 receptor antagonist. Br J Pharmacol 130:1606–1621
Sachdev P, Aniss AM (1994) Slowness of movement in melancholic depression. Biol Psychiatry 35:253–262
Sánchez C, Meier E (1997) Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 129:197–205
Sari Y, Miquel M-C, Brisorgueil M-J, Ruiz G, Doucet E, Hamon M and Vergé D (1999) Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies. Neuroscience 88:899–915
Sasaki-Adams DM, Kelley AE (2001) Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behavior. Neuropsychopharmacology 25:440–452
Skingle M, Beattie DT, Scopes DIC, Starkey SJ, Connor HE, Feniuk W, Tyers MB (1996) GR127935, a potent and selective 5-HT1D receptor antagonist. Behav Brain Res 73:157–161
Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249-258
Tecott LH, Chu HM, Brennan TJ (1998) Neurobehavioural analysis of 5-HT6 receptor null mice. Fourth IUPHAR satellite meeting on serotonin, Rotterdam, S1.2
Trillat AC, Malagié I, Bourin M, Jacquot C, Hen R, Gardier AM (1998) Homozygote mice deficient in serotonin 5-HT1B receptor and antidepressant effect of selective serotonin reuptake inhibitors. CR Seances Soc Biol Fil 192:1139–1147
Varnäs K, Hall H, Bonaventure P, Sedvall G (2001) Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human using [3H]GR 125743. Brain Res 915:47–57
Watson JM, Burton MJ, Price GW, Jones BJ, Middlemiss DN (1996). GR127935 acts as a partial agonist at recombinant human 5-HT1D and 5-HT1D receptors. Eur J Pharmacol 314:365–372
Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA, Lightowler S, Blackburn TP, Thomas D, Gager TL, Riley G, Holland V, Bromidge SM, Forbes IT, Middlemiss DN (2001) SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 41:186–199
Yamada J, Sugimoto Y (2001) Effects of 5-HT2 receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice. Eur J Pharmacol 427:221–225
Yan QS, Yan SE (2001) Activation of 5-HT1B/1D receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study. Eur J Pharmacol 418:55–64
Yan QS, Reith MEA,Yan S (2000) Enhanced accumbal dopamine release following 5-HT2A receptor stimulation in rats pretreated with intermittent cocaine. Brain Res 863:254–258
Acknowledgements
We thank Marianne Soubeyran for secretarial assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Millan, M.J., Veiga, S., Girardon, S. et al. Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. Psychopharmacology 168, 397–409 (2003). https://doi.org/10.1007/s00213-003-1389-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1389-y